4 results
To determine whether a second, booster, influenza vaccination leads to a higher seroprotection rate in SLE patients, as compared to a single vaccination.
Primary: Safety and tolerability of fingolimod 0,5 mg.Secundairy: Efficacy and quality of life.
To assess uptake (visual and quantitative) of 89Zr-ipilimumab in tumor lesions and biodistribution at start of nivolumab/ipilimumab therapy Secondary1. To determine the correlation between tumor targeting of ipilimumab and response to therapy.2. To…
The purpose of this study is to seek regulatory approval for use of fingolimod in a pediatric population with MS aged 10 to less than 18 years old. This study is conducted in line with the Pediatric Investigational Plan agreed with the EMA (under EU…